Clinical Trial Update: Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination. [Phase 4]

View source ↗

Summary

A Phase 4 study evaluated the immunogenicity and safety (reactogenicity) of Boostrix administered 10 years after a prior booster, in individuals with protection…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Pertussis
• Tetanus

Drugs mentioned

• Boostrix (Diphtheria, Tetanus, and Acellular Pertussis Vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Acellular Pertussis, Tetanus | Phase 4 | Status: COMPLETED | Results posted: 2017-03-30